Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

900
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
900
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Experimental RNAi02:15

Experimental RNAi

6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

3.7K
3.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

261
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
261
Lipid Absorption01:24

Lipid Absorption

868
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
868

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Foodborne Botulism in an Immunocompetent Adult Following the Consumption of a Prepackaged Soup.

Cureus·2026
Same author

Over-the-scope clips versus standard endoscopic therapy as first-line treatment for bleeding peptic ulcer disease: a systematic review and meta-analysis.

Annals of translational medicine·2026
Same author

Evaluation of a Meds-to-Beds Program to Reduce Readmissions After Percutaneous Coronary Intervention.

JACC. Advances·2026
Same author

Perceptibility of AI-revised content in pharmacy residency letters of intent.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis in cancer-related surgeries: A meta-analysis of efficacy and safety outcomes.

American heart journal plus : cardiology research and practice·2025
Same author

Percutaneous Transapical Bioprosthetic Leaflet Modification Facilitated Transfemoral Valve-in-Surgical Bioprosthetic Transcatheter Aortic Valve Replacement: Undermining Iatrogenic Coronary Obstruction With Radiofrequency Needle (UNICORN).

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025

Related Experiment Video

Updated: Sep 20, 2025

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.1K

Inclisiran: Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia.

Frances Hughes-Hubley1, Mina Iskander2, Angela Cheng-Lai1

  • 1From the Department of Pharmacy, Montefiore Medical Center, Bronx, NY.

Cardiology in Review
|June 6, 2022
PubMed
Summary

Inclisiran offers a novel, twice-yearly injection for patients with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) who do not reach lipid targets with statins alone. This new therapy shows significant low-density lipoprotein cholesterol (LDL-C) reduction with a good safety profile, though long-term outcomes are pending.

More Related Videos

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K
Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

10.8K

Related Experiment Videos

Last Updated: Sep 20, 2025

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.1K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K
Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

10.8K

Area of Science:

  • Cardiology
  • Pharmacology
  • Biotechnology

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic heart disease, and stroke.
  • Statins are primary treatments for hyperlipidemia but often insufficient for patients with genetic predispositions or established ASCVD.
  • Suboptimal lipid management contributes to persistent cardiovascular event risk.

Purpose of the Study:

  • To evaluate the efficacy and safety of inclisiran, a novel siRNA-based therapy, for managing LDL-C in specific patient populations.
  • To assess inclisiran's role as an adjunct therapy for patients with heterozygous familial hypercholesterolemia or clinical ASCVD on maximally tolerated statins.
  • To determine if inclisiran can help patients achieve target LDL-C levels when statins alone are inadequate.

Main Methods:

  • Inclisiran administration as a twice-yearly subcutaneous injection.
  • Clinical trials assessing LDL-C reduction in patients with heterozygous familial hypercholesterolemia and clinical ASCVD.
  • Evaluation of safety and tolerability profiles in conjunction with maximally tolerated statin therapy.

Main Results:

  • Inclisiran demonstrated significant and robust reduction in LDL-C levels across clinical trials.
  • The injectable therapy was associated with a favorable safety and tolerability profile.
  • Patients achieved target LDL-C levels more effectively when inclisiran was added to statin therapy.

Conclusions:

  • Inclisiran represents a significant advancement in lipid-lowering therapy, offering a convenient, infrequent dosing regimen.
  • This novel agent is effective in reducing LDL-C in high-risk patients, including those with familial hypercholesterolemia and established ASCVD.
  • Further research is ongoing to ascertain the long-term impact of inclisiran on major adverse cardiovascular events.